ClinicalTrials.gg
CompletedNCT01124123BIOBIUpdated Sep 26, 2012

Oral Bioavailability of Bilastine

A Phase 1 interventional study of Bilastine and Bilastine in Healthy, sponsored by Faes Farma, S.A.. Completed at 1 site in Spain. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-09-26.

Sponsored by Faes Farma, S.A. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of this study is to assess the absolute bioavailability of an oral bilastine formulation (test drug) compared to the endovenous administration of an IV bilastine formulation (control drug) in healthy volunteers.

Read the detailed description

Single centre, open label, cross-over, randomised, controlled, single dose study. The primary endpoint is the determination of plasma concentrations versus time (17 samples per subject at various time intervals after dosing) in order to assess the oral bioavailability of bilastine in healthy volunteers. Therefore the primary pharmacokinetic variable will be the area under the plasma concentration versus time curve from time zero to infinity (AUC 0-∞). Additionally the following pharmacokinetic variables will also be assessed: Cmax, AUC 0-t, tmax, Ae, Clr, t1/2. Additional objectives are to describe the safety and tolerability of a single administration of oral and endovenous bilastine in healthy volunteers.

Twelve healthy volunteers will be included. Each volunteer will take in random order one single dose of 20 mg oral bilastine and 10 mg IV bilastine with a minimum washout period of 14 days between them.

Bilastine plasma concentrations will be measured using a liquid chromatography/mass mass spectrometry (LC/MS/MS) micro method

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • Oral bioavailability
  • absorption
  • AUC
  • Bioequivalence
  • Bioavailability study
03

In context

Lead sponsor

Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers of either sex aged from ≥ 18 to ≤ 35 years of age.
  • between 19 and 29 Kg/m2.
  • Non smokers.
  • Judged to be in general good health based on medical history, physical examination and clinical laboratory tests.
  • Able to communicate well with the investigator and to comply with the requirements of the entire study.
  • Provision of written to participate.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women or with a positive pregnancy test. Subjects who do not agree to use an adequate method of during the study.
  • Intake of another medication in another clinical study within 4 months prior to the first study drug intake.
  • Regular use of any prescribed medication including medicinal herbs or OTC medication within 4 weeks of dosing.
  • A > 430 ms in males and a QTc> 450 ms in females. A HR \<55 bpm.
  • Existence of any surgical or medical condition which, in the judgement of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the IMP.
  • Known allergy/ to the study drug or its inactive ingredients.
  • Any clinical conditions or circumstances that in the opinion of the investigator would make the subject unsuitable for the study (e.g., hepatic impairment, renal impairment, mental impairment, cardiac disease).
  • Presence of surface antigen (HBsAg), antibody (HCV Ab) or 1 or HIV 2 antibodies at screening.
  • Subjects who have taken metabolic or transporter inducers/inhibitors during the 3 months prior to inclusion in the study.
  • Donation or loss of greater than 200 mL of blood within 12 weeks before entry to the study.
  • Blood transfusion within the prior 6 months to inclusion.
  • Ingestion of citrus fruits and cranberries or any fruit juice within 7 days prior to first dose of study medication.
  • Known current alcohol or drug abuse.
  • Excessive consumption of xanthine containing foods or drinks.
  • Mentally disabled subjects or subjects who by official order have been institutionalised must be excluded from participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Bilastine 20 mg

    Single dose 20 mg bilastine oral tablet. Test drug

    Drug: Bilastine

  • Active comparator
    Bilastine 10 mg

    Single dose 10 mg Bilastine endovenous. Control drug

    Drug: Bilastine

Interventions

06

What researchers measure

Primary outcomes

  1. The area under the plasma concentration versus time curve from time zero to infinity (AUC 0-∞ ).

    Bilastine bioavailability will be obtained from the oral AUC 0-∞ / endovenous AUC 0-∞ quotient.

    Time frame: 17 blood draws performed at: 0,25 - 0,5- 0,75 - 1 - 1,25 - 1,5 - 1,75 - 2 - 2,5 - 3 - 4 - 5 - 7 - 12 - 24 - 48 and 72 hours post administration.

Secondary outcomes

  1. Additional pharmacokinetic variables: Cmax, AUC 0-t, tmax, Ae, CLr and t ½

    * Cmax: Maximum plasma concentration; the highest concentration observed during a dosage interval * tmax: The time that Cmax was observed * AUC 0-t: The area under the plasma concentration versus time curve from time zero to the last time point * Ae: amount of accumulated unaltered drug in urine till the last time point * Clr: Renal clearance * t ½: Elimination halflife

    Time frame: 17 blood draws and urine collection during 72 hours post administration

  2. Safety and tolerability of a single dose administration of oral and endovenous bilastine

    Safety will be assessed during the study by monitoring adverse events (AEs), clinical laboratory test results (urinalysis, blood chemistry, and haematology), vital signs (including blood pressure, respiration, temperature, and heart rate, supine and standing), electrocardiogram (ECG) results, and abnormal findings upon physical examination.

    Time frame: A last Follow up visit will be performed 7 days after last drug intake

07

Study locations

1 site
  • Unidad de Investigacion Clinica. Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
08

References and documents

Publications

  • Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodriguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48(8):543-54. doi: 10.2165/11317180-000000000-00000. PubMed 19705924 ↗
  • Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E, Gedey S, Jahic M, Bednarczyk D. Interactions of bilastine, a new oral H(1) antihistamine, with human transporter systems. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:8-17. doi: 10.3109/01480545.2012.682653. Erratum In: Drug Chem Toxicol. 2012 Oct;35(4):472. PubMed 22616811 ↗
  • Sadaba B, Gomez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig. 2013 May;33(5):375-81. doi: 10.1007/s40261-013-0076-y. PubMed 23529786 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jun 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2010
First posted
May 14, 2010
Start
May 2010
Primary completionActual
Jun 2010
CompletionActual
Sep 2010
Last update
Sep 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01124123
Lead sponsor
Faes Farma, S.A.
Responsible party
Sponsor
First posted
May 14, 2010
Start date
May 2010
Primary completion
Jun 2010
Completion
Sep 2010
Last update
Sep 26, 2012

Study contacts

Belen Sadaba, MD
principal investigator · Unidad de Investigacion Clinica. Clinica Universidad Navarra (CUN)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion